Granulocyte colony stimulating factor long-acting - Genexine

Drug Profile

Granulocyte colony stimulating factor long-acting - Genexine

Alternative Names: G-CSF-hyFc; GCSF-hFc; GX-G03; GX-G3

Latest Information Update: 17 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genexine
  • Developer Boryung Pharmaceutical; Genexine; Ilkogen
  • Class Adjuvants; Glycoproteins; Granulocyte colony-stimulating factors; Granulocyte-macrophage colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Haematopoietic cell growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 02 Mar 2016 Phase-II clinical trials in Neutropenia (Chemotherapy-induced) in Bulgaria (SC) (EudraCT2015-002693-20)
  • 16 Oct 2015 GX G3 licensed to Tasly in China
  • 28 Jan 2015 Genexine completes a phase I trial in Neutropenia (in volunteers) in South Korea (NCT01951027)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top